Oops! This Content is Members Only
The content you’re trying to view is for members only. Please register in order to access this content.
Registered users, please login to access this content.
Myeloma News
Powered By:
- FDA Grants Accelerated Approval To Melphalan Flufenamide For Relapsed Or Refractory Multiple Myeloma
- FDA Approves Oncopeptides’ PEPAXTO® ( Melphalan Flufenamide) For Patients With Relapsed Or Refractory Multiple Myeloma
- The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy
- CAR T-cell Therapy Generates Lasting Remissions In Patients With Multiple Myeloma
- Cartesian Therapeutics Initiates Phase 2 Clinical Trial of First RNA-Engineered Cell Therapy for Frontline Cancer
- New Recommendations Aim To Eliminate Racial Bias In Myeloma Trials
- Pfizer Initiates Pivotal Phase 2 MagnetisMM-3 Trial of BCMA-CD3 Bispecific Antibody Elranatamab (PF-06863135) in Multiple Myeloma
- Cancer Drug Shows Potent Activity in the Lab Against SARS-CoV-2, Including New Variants
- Oncopeptides Enrolls the First Patient in the Phase 3 LIGHTHOUSE Combination Study in Multiple Myeloma
- FDA Approves Karyopharm’s Xpovio To Treat Multiple Myeloma After At Least One Prior Therapy